• Citer

Safety and efficacy of tamoxifen in non-ambulant patients with Duchenne muscular dystrophy: a multicentre, randomised, double–blind, placebo–controlled, phase 3 trial (TAMDMD Group B)

par Henzi, Bettina Cornelia;Putananickal, Niveditha;Schmidt, Simone;Nagy, Sara;Rubino–Nacht, Daniela;Schaedelin, Sabine;Amthor, Helge;Childs, Anne–Marie –M;Deconinck, Nicolas ;Horrocks, Iain;Houwen–van Opstal, Saskia;Laugel, Vincent;Lobato, Mercedes Lopez;Osorio, Andrés Nascimento;Schara–Schmidt, Ulrike;Spinty, Stefan;von Moers, Arpad;Lawrence, Fiona;Hafner, Patricia;Dorchies, Olivier O.M.;Fischer, Dirk
Référence Neuromuscular disorders, 47, 105275
Publication Publié, 2025-02

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Titre:	Safety and efficacy of tamoxifen in non-ambulant patients with Duchenne muscular dystrophy: a multicentre, randomised, double–blind, placebo–controlled, phase 3 trial (TAMDMD Group B)
Auteur:	Henzi, Bettina Cornelia; Putananickal, Niveditha; Schmidt, Simone; Nagy, Sara; Rubino–Nacht, Daniela; Schaedelin, Sabine; Amthor, Helge; Childs, Anne–Marie –M; Deconinck, Nicolas; Horrocks, Iain; Houwen–van Opstal, Saskia; Laugel, Vincent; Lobato, Mercedes Lopez; Osorio, Andrés Nascimento; Schara–Schmidt, Ulrike; Spinty, Stefan; von Moers, Arpad; Lawrence, Fiona; Hafner, Patricia; Dorchies, Olivier O.M.; Fischer, Dirk
Informations sur la publication:	Neuromuscular disorders, 47, 105275
Statut de publication:	Publié, 2025-02
Sujet CREF:	Neurologie
	Pédiatrie
	Génétique clinique
Mots-clés:	Corticosteroid naive
	Duchenne muscular dystrophy
	Motor function measurement
	Non-ambulant duchenne muscular dystrophy
	Tamoxifen
Note générale:	SCOPUS: ar.j
Langue:	Anglais
Identificateurs:	urn:issn:0960-8966
	info:doi/10.1016/j.nmd.2025.105275
	info:pii/S0960896625000021
	info:scp/85216105139
	info:pmid/39879732